NEWTON, Mass.--(BUSINESS WIRE)--Sept. 11, 2006--Novelos Therapeutics, Inc. (OTCBB: NVLT), a biotechnology company focused on the development of therapeutics to treat cancer and hepatitis, today announced that the Company has received a notice of allowance from the U.S. Patent and Trademark Office for its patent application extending the composition and method of use claims relating to NOV-002, Novelos' lead compound in Phase 3 development for non-small cell lung cancer under a Special Protocol Assessment (SPA) and Fast Track.
